[BQ Editor’s Note: This article is reproduced here in its entirety with the express permission of the original publisher Genetic Engineering & Biotechnology News (GEN). The GEN publication date was September 15, 2015. A Figure and two tables have been removed and readers should refer to the original GEN article to review the details of these graphic elements, The GEN artricle can be found at the following link: http://www.genengnews.com/gen-articles/continuous-production-of-exosomes/5580/] Interest in exosomes has grown of late, particularly because these sub-cellular vesicles have been seen to take part in functional interactions with antigen-presenting cells, and in the modulation of the immune response in vivo. For example, tumor exosomes are thought to participate in metastasis of tumor cells, seeding tumor-draining lymph nodes prior to tumor cell migration, and increasing their motility. These nanovesicles have already proven themselves as having such therapeutic potential as the repair of cardiac tissue after heart attack, which had been axiomatically unheard prevoiously in the annals of cardiology. Clinical trials for many indications, such as using dendritic cell-derived exosomes to facilitate immune response to cancers, are now underway. As their content is a fingerprint of the type and status of the cell generating them, the prognostic potential of exosomes as biomarkers, including biomarkers that could be used to predict cell therapy outcome, is being explored. Current work on exosome manufacturing involves their regulatory-compliant generation in an appropriate cell line and separation from such process-related contaminants as other extracellular vesicles.
Login Or Register To Read Full Story